^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    pumitamig (BNT327)

    i
    Other names: BNT327, BMS986545, PM8002, PM 8002, PM-8002, BNT 327, BNT-327, BMS-986545
    Company:
    BMS, BioNTech
    Drug class:
    PD-L1 inhibitor, VEGF-A inhibitor
    Related drugs:
    7d
    DB-1311-201: DB-1311 in Combination with BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors (2025-523895-22-00)
    P1/2, N=102, Not yet recruiting, Dualitybio Inc. | N=57 --> 102
    Enrollment change
    |
    pumitamig (BNT327) • BNT324
    10d
    A Study of PM8002 Injection in Combination With Standard Chemotherapy as First Line Therapy in MPM (clinicaltrials.gov)
    P2, N=31, Completed, Biotheus Inc. | Recruiting --> Completed | N=55 --> 31 | Trial completion date: Jun 2026 --> Mar 2026 | Trial primary completion date: Jun 2026 --> Mar 2026
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    cisplatin • carboplatin • pemetrexed • pumitamig (BNT327)
    15d
    CA052-002: A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=1109, Recruiting, Bristol-Myers Squibb | Trial completion date: Jul 2028 --> Aug 2031 | Trial primary completion date: Jul 2028 --> Aug 2031
    Trial completion date • Trial primary completion date • First-in-human
    |
    Opdivo (nivolumab) • docetaxel • pumitamig (BNT327)
    16d
    A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206) (clinicaltrials.gov)
    P1/2, N=198, Recruiting, Bristol-Myers Squibb | N=129 --> 198
    Enrollment change
    |
    Yervoy (ipilimumab) • pumitamig (BNT327)
    25d
    CA2660001: A Study of Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants with Unresectable Stage III NSCLC (2025-523576-23-00)
    P2/3, N=62, Not yet recruiting, Bristol-Myers Squibb Services Unlimited Company
    New P2/3 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Imfinzi (durvalumab) • pumitamig (BNT327)
    27d
    PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=404, Active, not recruiting, Biotheus Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    paclitaxel • topotecan • pumitamig (BNT327)
    1m
    CA2660002: A Study of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ? 50% (2025-523586-18-00)
    P2/3, N=15, Not yet recruiting, Bristol-Myers Squibb Services Unlimited Company
    New P2/3 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • pumitamig (BNT327)
    1m
    DB-1311-201: DB-1311 in Combination with BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors (2025-523895-22-00)
    P1/2, N=57, Not yet recruiting, Dualitybio Inc.
    New P1/2 trial
    |
    pumitamig (BNT327) • BNT324
    1m
    Ph1/2 Trial Of Navlimetostat With Pumitamig In MTAP-Deficient Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=17, Not yet recruiting, M.D. Anderson Cancer Center
    New P1/2 trial
    |
    ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • MTAP (Methylthioadenosine Phosphorylase) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    navlimetostat (BMS-986504) • pumitamig (BNT327)
    1m
    DB-1305-O-1001: First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=1123, Active, not recruiting, DualityBio Inc. | Recruiting --> Active, not recruiting | Trial completion date: Jun 2025 --> Sep 2027 | Trial primary completion date: Jun 2025 --> Aug 2027
    Enrollment closed • Trial completion date • Trial primary completion date • First-in-human
    |
    Keytruda (pembrolizumab) • pumitamig (BNT327)
    1m
    ROSETTA GI 204: A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204) (clinicaltrials.gov)
    P2/3, N=690, Recruiting, Bristol-Myers Squibb
    Trial initiation date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    HER-2 negative
    |
    Opdivo (nivolumab) • 5-fluorouracil • pumitamig (BNT327)
    1m
    ROSETTA CRC-203: A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2/3, N=990, Recruiting, Bristol-Myers Squibb
    Trial initiation date
    |
    Avastin (bevacizumab) • 5-fluorouracil • irinotecan • leucovorin calcium • pumitamig (BNT327)